US FDA re-extends comment deadline on generic drug user fee programme
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has extended until 23 February the deadline for stakeholders to submit comments on the agency's plans to create a user fee programme for the generic drugs industry1.